Skip to main content
PMC home page
International Journal of Methods in Psychiatric Research logoLink to International Journal of Methods in Psychiatric Research
. 2006 Mar 24;14(4):167–185. doi: 10.1002/mpr.6

The Netherlands XTC Toxicity (NeXT) study: objectives and methods of a study investigating causality, course, and clinical relevance

Maartje ML De Win 1,2,✉, Gerry Jager 3, Hylke KE Vervaeke 4, Thelma Schilt 5, Liesbeth Reneman 1, Jan Booij 6, Frank C Verhulst 7, Gerard J Den Heeten 1, Nick F Ramsey 3, Dirk J Korf 4, Wim Van Den Brink 8
PMCID: PMC6878462  PMID: 16395871

Abstract

This paper describes the objectives and methods of The Netherlands XTC Toxicity (NeXT) study focussing on the causality, course, and clinical relevance of ecstasy neurotoxicity. Previous studies suggest that ecstasy (3,4 methylenedioxymethamphetamine, MDMA, XTC) is toxic toward brain serotonin axons, but most of these studies have serious methodological limitations. The current study is a combination of different approaches with three substudies: (1) a cross‐sectional substudy among heavy ecstasy users and controls with variation in drug use, which will provide information about potential neurotoxic consequences of ecstasy in relation to other drugs; (2) a prospective cohort substudy in ecstasy‐naive subjects with high risk for future ecstasy use, which will provide information on the causality and short‐term course of ecstasy use and potential neurotoxicity, and (3) a retrospective cohort substudy in lifetime ecstasy users and matched controls of an existing epidemiological sample that will provide information on long‐term course and outcome of ecstasy use in the general population. Neurotoxicity is studied using (a) different imaging techniques (β‐CIT SPECT, [In this paper, the term ‘MDMA’ is used for ecstasy known to contain pure MDMA (laboratory conditions); the term ‘ecstasy’ is used for tablets/powder thought to be ecstasy although containment of MDMA only was not confirmed (general practice).]H‐MR spectroscopy, diffusion tensor imaging, perfusion weighted imaging and functional magnetic resonance imaging), and (b) neuropsychological and psychiatric assessments of memory, depression, and personality. The combined results will lead to conclusions that can be used in prevention messages, clinical decision making, and the development of an (inter)national ecstasy policy. Copyright © 2005 John Wiley & Sons, Ltd.

Keywords: ecstasy, MDMA, serotonin, brain imaging, neurotoxicity

Full Text

The Full Text of this article is available as a PDF (430.2 KB).

References

  1. Abraham MD, Kaal HL, Cohen PDA. Licit and Illicit Drug uses in the Netherlands. Amsterdam: Cedro/Mets & Schilt, 2002. [Google Scholar]
  2. Achenbach TM. Manual for the Child Behavior Checklist/4‐18 and 1991 Profile. Burlington: University of Vermont Department of Psychiatry, 1991. [Google Scholar]
  3. Back‐Madruga C, Boone KB, Chang L, Grob CS, Lee A, Nations H, Poland RE. Neuropsychological effects of 3,4‐methylenedioxymethamphetamine (MDMA or ecstasy) in recreational users. Clin Neuropsychol 2003; 17: 446–59. [DOI] [PubMed] [Google Scholar]
  4. Bardo MT, Donohew RL, Harrington NG. Psychobiology of novelty seeking and drug seeking behavior. Behav Brain Res 1996; 77: 23–43. [DOI] [PubMed] [Google Scholar]
  5. Bechara A, Damasio AR, Damasio H, Anderson SW. Insensitivity to future consequences following damage to human prefrontal cortex. Cognition 1994; 50: 7–15. [DOI] [PubMed] [Google Scholar]
  6. Beck AT, Steer RA. Internal consistencies of the original and revised Beck Depression Inventory. J Clin Psychol 1984; 40: 1365–7. [DOI] [PubMed] [Google Scholar]
  7. Beck AT, Ward CH, Mendelson M, Mock J, Erbauch J. An inventory for measuring depression. Arch Gen Psych 1961; 4: 561–71. [DOI] [PubMed] [Google Scholar]
  8. Bender E. FDA approves study of ecstasy in some terminally ill patients. Psychiatric News 2005; 40: 46. [Google Scholar]
  9. Benton AL, Varney NR, Hamsher KS. Visuo‐spatial judgement: a clinical test. Arch Neurol 1978; 35: 364–7. [DOI] [PubMed] [Google Scholar]
  10. Bhattachary S, Powell JH. Recreational use of 3,4‐methyl‐enedioxymethamphetamine (MDMA) or ‘ecstasy’: evidence for cognitive impairment. Psychol Med 2001; 31: 647–58. [DOI] [PubMed] [Google Scholar]
  11. Bolla KI, McCann UD, Ricaurte GA. Memory impairment in abstinent MDMA (‘ecstasy’) users. Neurology 1998; 51: 1532–7. [DOI] [PubMed] [Google Scholar]
  12. Bond AJ, Verheyden SL, Wingrove J, Curran HV. Angry cognitive bias, trait aggression and impulsivity in substance users. Psychopharmacology 2004; 171: 331–9. [DOI] [PubMed] [Google Scholar]
  13. Boot BP, McGregor IS, Hall W. MDMA (ecstasy) neurotoxicity: assessing and communicating the risks. Lancet 2000; 355: 1818–21. [DOI] [PubMed] [Google Scholar]
  14. Bouman TK, Luteijn F, Albersnagel FA, Van der Ploeg FAE. Enige ervaringen met de Beck Depression Inventory (BDI). Gedrag 1985; 13: 13–24. [Google Scholar]
  15. Buchert R, Thomasius R, Nebeling B, Petersen K, Obrocki J, Jenicke L, Wilke F, Wartberg L, Zapletalova P, Clausen M. Long‐term effects of ‘ecstasy’ use on serotonin transporters of the brain investigated by PET. J Nucl Med 2003; 44: 375–84. [PubMed] [Google Scholar]
  16. Buchert R, Thomasius R, Wilke F, Petersen K, Nebeling B, Obrocki J, Schulze O, Schmidt U, Clausen M. A voxel‐based PET investigation of the long‐term effects of ‘ecstasy’ consumption on brain serotonin transporters. Am J Psych 2004; 161: 1181–9. [DOI] [PubMed] [Google Scholar]
  17. Butler GK, Montgomery AM. Impulsivity, risk taking and recreational ‘ecstasy’ (MDMA) use. Drug Alcohol Depend 2004; 76: 55–62. [DOI] [PubMed] [Google Scholar]
  18. Chang L, Ernst T, Grob CS, Poland RE. Cerebral 1H MRS alterations in recreational 3, 4‐methylene‐dioxymethamphetamine (MDMA, ‘ecstasy’) users. J Magn Reson Imaging 1999; 10: 521–6. [DOI] [PubMed] [Google Scholar]
  19. Chang L, Grob CS, Ernst T, Itti L, Mishkin FS, Jose‐Melchor R, Poland RE. Effect of ecstasy [3,4‐methylenedioxymethamphetamine (MDMA)] on cerebral blood flow: a co‐registered SPECT and MRI study. Psychiatr Res 2000; 98: 15–28. [DOI] [PubMed] [Google Scholar]
  20. Check E. Psychedelic drugs: the ups and downs of ecstasy. Nature 2004; 429: 126–8. [DOI] [PubMed] [Google Scholar]
  21. Cohen Z, Bonvento G, Lacombe P, Hamel E. Serotonin in the regulation of brain microcirculation. Prog Neurobiol 1996; 50: 335–62. [DOI] [PubMed] [Google Scholar]
  22. Daumann J, Fischermann T, Heekeren K, Henke K, Thron A, Gouzoulis‐Mayfrank E. Memory‐related hippocampal dysfunction in poly‐drug ecstasy (3,4‐methylenedioxymethamphetamine) users. Psycho‐pharmacology (Berl) 2005; 180: 607–11. [DOI] [PubMed] [Google Scholar]
  23. Daumann J, Hensen G, Thimm B, Rezk M, Till B, Gouzoulis‐Mayfrank E. Self‐reported psychopathological symptoms in recreational ecstasy (MDMA) users are mainly associated with regular cannabis use: further evidence from a combined cross‐sectional/longitudinal investigation. Psychopharmacology 2004a; 173: 398–404. [DOI] [PubMed] [Google Scholar]
  24. Daumann J, Fischermann T, Pilatus U, Thron A, Moeller‐Hartmann W, Gouzoulis‐Mayfrank E. Proton magnetic resonance spectroscopy in ecstasy (MDMA) users. Neurosci. Lett. 2004b; 362: 113–16. [DOI] [PubMed] [Google Scholar]
  25. Daumann J, Fischermann T, Heekeren K, Thron A, Gouzoulis‐Mayfrank E. Neural mechanisms of working memory in ecstasy (MDMA) users who continue or discontinue ecstasy and amphetamine use: evidence from an 18‐month longitudinal functional magnetic resonance imaging study. Biol Psychiatry 2004c; 56: 349–55. [DOI] [PubMed] [Google Scholar]
  26. Daumann J, Fimm B, Willmes K, Thron A, Gouzoulis‐Mayfrank E. Cerebral activation in abstinent ecstasy (MDMA) users during a working memory task: a functional magnetic resonance imaging (fMRI) study. Brain Res Cogn Brain Res 2003a; 16: 479–87. [DOI] [PubMed] [Google Scholar]
  27. Daumann J, Schnitker R, Weidemann J, Schnell K, Thron A, Gouzoulis‐Mayfrank E. Neural correlates of working memory in pure and polyvalent ecstasy (MDMA) users. Neuroreport 2003b; 14: 1983–7. [DOI] [PubMed] [Google Scholar]
  28. De Win MML, Habraken JBA, Reneman L, Van den Brink W, Den Heeten GJ, Booij J. Validation of [123I]‐CIT SPECT to assess serotonin transporters in vivo in humans: a double‐blind, placebo‐controlled, crossover study with the selective serotonin reuptake inhibitor citalopram. Neuropsychopharmacology 2005; 30: 996–1005. [DOI] [PubMed] [Google Scholar]
  29. De Win MML, Reneman L, Reitsma JB, den Heeten GJ, Booij J, Van den Brink W. Mood disorders and serotonin transporter density in ecstasy users–the influence of long‐term abstention, dose, and gender. Psychopharmacology (Berl) 2004; 173: 376–82. [DOI] [PubMed] [Google Scholar]
  30. Doblin R. A clinical plan for MDMA (ecstasy) in the treatment of posttraumatic stress disorder (PTSD): partnering with the FDA. J. Psychoactive Drugs 2002; 34: 185–94. [DOI] [PubMed] [Google Scholar]
  31. Drugs Informatie en Monitoring Systeem . Rapportage gegevens 2002. Utrecht: DIMS/Trimbos‐instituut, 2003. [Google Scholar]
  32. Dughiero G, Schifano F, Forza G. Personality dimensions and psychopathological profiles of ecstasy users. Hum Psychopharmacol 2001; 16: 635–9. [DOI] [PubMed] [Google Scholar]
  33. Feij JA, Van Zuilen RW. Handleiding bij de spanningsbehoeftelijst (SBL). Lisse: Swets & Zeitlinger, 1984. [Google Scholar]
  34. Feij JA, Van Zuilen RW, Gazendam A. De ontwikkeling van een Nederlandse vragenlijst voor sensation seeking: de spanningsbehoeftelijst (SBL). Gedrag 1982; 10: 364–83. [Google Scholar]
  35. Gerra G, Angioni L, Zaimovic A, Moi G, Bussandri M, Bertacca S, Santoro G, Gardini S, Caccavari R, Nicoli MA. Substance use among high‐school students: relationships with temperament, personality traits, and parental care perception. Substance Use and Misuse 2004; 39: 345–67. [DOI] [PubMed] [Google Scholar]
  36. Gerra G, Zaimovic A, Ferri M, Zambelli U, Timpano M, Neri E, Marzocchi GF, Delsignore R, Brambilla F. Long‐lasting effects of (±)3,4‐methylene‐dioxymethamphetamine (ecstasy) on serotonin system function in humans. Biological Psychiatry 2000; 47: 127–36. [DOI] [PubMed] [Google Scholar]
  37. Gijsman HJ, Verkes RJ, Van Gerven JM, Cohen AF. MDMA study. Neuropsychopharmacology 1999; 21: 597. [DOI] [PubMed] [Google Scholar]
  38. Gouzoulis‐Mayfrank E, Daumann J, Tuchtenhagen F, Pelz S, Becker S, Kunert HJ, Fimm B, Sass H. Impaired cognitive performance in drug free users of recreational ecstasy (MDMA). J Neurol Neurosurg Psychiatry 2000; 68: 719–25. [DOI] [PMC free article] [PubMed] [Google Scholar]
  39. Graham FK, Kendall BS. Memory‐for‐design: revised general manual. Percept Motor Skills 1960; 11: 147–88. [Google Scholar]
  40. Gronwall DMA. Paced Auditory Serial‐Addition Task: A measure of recovery from concussion. Perceptual and Motor Skills 1977; 44: 367–73. [DOI] [PubMed] [Google Scholar]
  41. Hanyu S, Ikeguchi K, Imai H, Imai N, Yoshida M. Cerebral infarction associated with 3,4‐methylenedioxymetham‐phetamine (‘ecstasy’) abuse. Eur Neurol 1995; 35: 173. [DOI] [PubMed] [Google Scholar]
  42. Hatzidimitriou G, McCann UD, Ricaurte GA. Altered serotonin innervation patterns in the forebrain of monkeys treated with (±)3,4‐methylenedioxymethamphetamine seven years previously: factors influencing abnormal recovery. Journal of Neuroscience 1999; 19: 5096–107. [DOI] [PMC free article] [PubMed] [Google Scholar]
  43. Henke K, Buck A, Weber B, Wieser HG. Human hippocampus establishes associations in memory. Hippocampus 1997; 7: 249–56. [DOI] [PubMed] [Google Scholar]
  44. Hofstra MB, Van der Ende J, Verhulst FC. Child and adolescent problems predict DSM‐IV disorders in adulthood: a 14‐year follow‐up of a Dutch epidemiological sample. J Am Acad Child Adolesc Psychiatry 2002; 41: 182–9. [DOI] [PubMed] [Google Scholar]
  45. Huether G, Zhou D, Ruther E. Causes and consequences of the loss of serotonergic presynapses elicited by the consumption of 3,4‐methylenedioxymethamphetamine (MDMA, ‘ecstasy’) and its congeners. J Neural Transm 1997; 104: 771–94. [DOI] [PubMed] [Google Scholar]
  46. Jansen KL, Forrest AR. Toxic effect of MDMA on brain serotonin neurons. Lancet 1999; 353: 1270–1. [DOI] [PubMed] [Google Scholar]
  47. Kish SJ. What is the evidence that ecstasy (MDMA) can cause Parkinson's disease? Mov Disord 2003; 18: 1219–23. [DOI] [PubMed] [Google Scholar]
  48. Korf DJ, Nabben T, Benschop A. Antenne 2003. Trends in alcohol, tabak en drugs bij jonge Amsterdammers. Amsterdam: Rozenberg Publishers, 2004. [Google Scholar]
  49. Kuniyoshi SM, Jankovic J. MDMA and Parkinsonism. N Engl J Med 2003; 349: 96–7. [DOI] [PubMed] [Google Scholar]
  50. Laruelle M, Baldwin RM, Malison RT, Zea‐Ponce Y, Zoghbi SS, Al Tikriti MS, Sybirska EH, Zimmermann RC, Wisniewski G, Neumeyer JL, Milius RA, Wang S, Smith EO, Roth RH, Charney DS, Hoffer PB, Innis RB. SPECT imaging of dopamine and serotonin transporters with [123I]ß‐ CIT: pharmacological characterization of brain uptake in nonhuman primates. Synapse 1993; 13: 295–309. [DOI] [PubMed] [Google Scholar]
  51. Lee GYF, Gong GWK, Vrodos N, Brophy PB. ‘Ecstasy’‐induced subarachnoid haemorrhage: an under‐reported neurological complication? J Clin Neurosci 2003; 10: 705–7. [DOI] [PubMed] [Google Scholar]
  52. Lesch KP, Bengel D, Heils A, Sabol SZ, Greenberg BD, Petri S, Benjamin J, Muller CR, Hamer DH, Murphy DL. Association of anxiety‐related traits with a polymorphism in the serotonin transporter gene regulatory region. Science 1996; 274: 1527–31. [DOI] [PubMed] [Google Scholar]
  53. Lieb R, Schuetz CG, Pfister H, Von Sydow K, Wittchen HU. Mental disorders in ecstasy users: a prospective‐longitudinal investigation. Drug and Alcohol Dependence 2002; 68: 195–207. [DOI] [PubMed] [Google Scholar]
  54. Liechti ME, Gamma A, Vollenweider FX. Gender differences in the subjective effects of MDMA. Psychopharmacology (Berl) 2001; 154: 161–8. [DOI] [PubMed] [Google Scholar]
  55. Lindeboom J, Matto D. Digit series and Knox cubes as concentration tests for elderly subjects. Tijdschr Gerontol Geriatr 1994; 25: 63–8. [PubMed] [Google Scholar]
  56. Malberg JE, Seiden LS. Small changes in ambient temperature cause large changes in 3,4‐methylene‐dioxymethamphetamine (MDMA)‐induced serotonin neurotoxicity and core body temperature in the rat. J Neurosci 1998; 18: 5086–94. [DOI] [PMC free article] [PubMed] [Google Scholar]
  57. McCann UD, Mertl M, Eligulashvili V, Ricaurte GA. Cognitive performance in (+/−) 3,4‐methylene‐dioxymethamphetamine (MDMA, ‘ecstasy’) users: a controlled study. Psychopharmacology (Berl) 1999; 143: 417–25. [DOI] [PubMed] [Google Scholar]
  58. McCann UD, Ricaurte GA. Caveat emptor: editors beware. Neuropsychopharmacology 2001; 24: 333–6. [DOI] [PubMed] [Google Scholar]
  59. McCann UD, Szabo Z, Scheffel U, Dannals RF, Ricaurte GA. Positron emission tomographic evidence of toxic effect of MDMA (‘ecstasy’) on brain serotonin neurons in human beings. Lancet 1998; 352: 1433–7. [DOI] [PubMed] [Google Scholar]
  60. McCardle K, Luebbers S, Carter JD, Croft RJ, Stough C. Chronic MDMA (ecstasy) use, cognition and mood. Psychopharmacology (Berl) 2004; 173: 434–9. [DOI] [PubMed] [Google Scholar]
  61. McQueen JK, Wilson H, Fink G. Estradiol‐17 beta increases serotonin transporter (SERT) mRNA levels and the density of SERT‐binding sites in female rat brain. Brain Res Mol Brain Res 1997; 45: 13–23. [DOI] [PubMed] [Google Scholar]
  62. Meneses A. 5‐HT system and cognition. Neuroscience and Biobehavioral Reviews 1999; 23: 1111–25. [DOI] [PubMed] [Google Scholar]
  63. Miller BL, Chang L, Booth R, Ernst T, Cornford M, Nikas D, McBride D, Jenden DJ. In vivo 1H MRS choline: correlation with in vitro chemistry/histology. Life Sci 1996; 58: 1929–35. [DOI] [PubMed] [Google Scholar]
  64. Mintzer S, Hickenbottom S, Gilman S. Parkinsonism after taking ecstasy N Engl J Med 1999; 340: 1443. [DOI] [PubMed] [Google Scholar]
  65. Monshouwer K, Van Dorsselaer S, Gorter A, Verdurmen J, Vollebergh W. Jeugd en riskant gedrag. Kerngegevens uit het peilstationsonderzoek 2003. Utrecht: Trimbos Institute, 2004. [Google Scholar]
  66. Morgan JF. Toxic effect of MDMA on brain serotonin neurons. Lancet 1999; 353: 1268–9. [DOI] [PubMed] [Google Scholar]
  67. Morgan MJ. Recreational use of ‘ecstasy’ (MDMA) is associated with elevated impulsivity. Neuropsychopharmacology 1998; 19: 252–64. [DOI] [PubMed] [Google Scholar]
  68. Morgan MJ. Ecstasy (MDMA): a review of its possible persistent psychological effects. Psychopharmacology (Berl) 2000; 152: 230–48. [DOI] [PubMed] [Google Scholar]
  69. Morgan MJ, McFie L, Fleetwood H, Robinson JA. Ecstasy (MDMA): are the psychological problems associated with its use reversed by prolonged abstinence? Psychopharmacology (Berl) 2002; 159: 294–303. [DOI] [PubMed] [Google Scholar]
  70. Morton AJ, Hickey MA, Dean LC. Methamphetamine toxicity in mice is potentiated by exposure to loud music. Neuroreport 2001; 12: 3277–81. [DOI] [PubMed] [Google Scholar]
  71. Nelson HE. The revised national adult reading test manual. Windsor: NFER‐Nelson, 1991. [Google Scholar]
  72. Netherlands National Drug Monitor . Annual Report 2003. Utrecht: Trimbos Institute, 2003. [Google Scholar]
  73. O'Suilleabhain P, Giller C. Rapidly progressive parkinsonism in a self‐reported user of ecstasy and other drugs. Mov Disord 2003; 18: 1378–81. [DOI] [PubMed] [Google Scholar]
  74. Parrott AC. Human research on MDMA (3,4‐methylenedioxymethamphetamine) neurotoxicity: cognitive and behavioural indices of change. Neuropsychobiology 2000; 42: 17–24. [DOI] [PubMed] [Google Scholar]
  75. Parrott AC, Sisk E, Turner JJD. Psychobiological problems in heavy ‘ecstasy’ (MDMA) polydrug users. Drug and Alcohol Dependence 2000; 60: 105–10. [DOI] [PubMed] [Google Scholar]
  76. Parrott AC. Human psychopharmacology of ecstasy (MDMA): a review of 15 years of empirical research. Hum Psychopharmacol 2001; 16: 557–77. [DOI] [PubMed] [Google Scholar]
  77. Parrott AC. MDMA (3,4‐Methylenedioxymethampheta‐mine) or ecstasy: the neuropsychobiological implications of taking it at dances and raves. Neuropsychobiology 2004; 50: 329–35. [DOI] [PubMed] [Google Scholar]
  78. Patton JH, Stanford MS, Barratt ES. Factor structure of the Barratt Impulsiveness Scale. Journal of Clinical Psychology 1995; 51: 768–74. [DOI] [PubMed] [Google Scholar]
  79. Pouwels PJ, Frahm J. Regional metabolite concentrations in human brain as determined by quantitative localized proton MRS. Magn Reson Med 1998; 39: 53–60. [DOI] [PubMed] [Google Scholar]
  80. Ramsey NF, Jansma JM, Jager G, Van Raalten T, Kahn RS. Neurophysiological factors in human information processing capacity. Brain 2004; 127: 517–25. [DOI] [PubMed] [Google Scholar]
  81. Reneman L, Booij J, De Bruin K, Reitsma JB, De Wolff FA, Gunning WB, Den Heeten GJ, Van den Brink W. Effects of dose, sex, and long‐term abstention from use on toxic effects of MDMA (ecstasy) on brain serotonin neurons. Lancet 2001a; 358: 1864–9. [DOI] [PubMed] [Google Scholar]
  82. Reneman L, Booij J, Habraken JB, De Bruin K, Hatzidimitriou G, Den Heeten GJ, Ricaurte GA. Validity of [123I]ß‐CIT SPECT in detecting MDMA‐induced serotonergic neurotoxicity. Synapse 2002a; 46: 199–205. [DOI] [PubMed] [Google Scholar]
  83. Reneman L, Booij J, Schmand B, Van den Brink W, Gunning B. Memory disturbances in ‘ecstasy’ users are correlated with an altered brain serotonin neurotrans‐ mission. Psychopharmacology (Berl) 2000a; 148: 322–4. [DOI] [PubMed] [Google Scholar]
  84. Reneman L, Habraken JB, Majoie CB, Booij J, Den Heeten GJ. MDMA (‘ecstasy’) and its association with cerebrovascular accidents: preliminary findings. Am J Neuroradiol 2000b; 21: 1001–7. [PMC free article] [PubMed] [Google Scholar]
  85. Reneman L, Lavalaye J, Schmand B, De Wolff FA, Van den Brink W, Den Heeten GJ, Booij J. Cortical serotonin transporter density and verbal memory in individuals who stopped using 3,4‐methylenedioxymethamphetamine (MDMA or ‘ecstasy’): preliminary findings. Arch. Gen. Psychiatry 2001b; 58: 901–6. [DOI] [PubMed] [Google Scholar]
  86. Reneman L, Majoie CB, Habraken JB, Den Heeten GJ. Effects of ecstasy (MDMA) on the brain in abstinent users: initial observations with diffusion and perfusion MR imaging. Radiology 2001c; 220: 611–17. [DOI] [PubMed] [Google Scholar]
  87. Reneman L, Majoie CB, Flick H, Den Heeten GJ. Reduced N‐acetylaspartate levels in the frontal cortex of 3,4‐methylenedioxymethamphetamine (ecstasy) users: preliminary results. Am J Neuroradiol 2002b; 23: 231–7. [PMC free article] [PubMed] [Google Scholar]
  88. Reneman L, Majoie CB, Schmand B, Van den Brink W, Den Heeten GJ. Prefrontal N‐acetylaspartate is strongly associated with memory performance in (abstinent) ecstasy users: preliminary report. Biol Psychiatry 2001d; 50: 550–4. [DOI] [PubMed] [Google Scholar]
  89. Rey A. L'examen clinique en psychologie. Paris: Presses Universitaires de France, 1964. [Google Scholar]
  90. Ricaurte GA, Martello AL, Katz JL, Martello MB. Lasting effects of (+−)‐3,4‐methylenedioxymethamphetamine (MDMA) on central serotonergic neurons in nonhuman primates: neurochemical observations. J Pharmacol Exp Ther 1992; 261: 616–22. [PubMed] [Google Scholar]
  91. Ricaurte GA, Yuan J, McCann UD. (±)3,4‐Methylenedioxymethamphetamine (‘ecstasy’)‐induced serotonin neurotoxicity: studies in animals. Neuropsychobiology 2000; 42: 5–10. [DOI] [PubMed] [Google Scholar]
  92. Roiser JP, Sahakian BJ. Relationship between ecstasy use and depression: a study controlling for poly‐drug use. Psychopharmacology (Berl) 2004; 173: 411–17. [DOI] [PMC free article] [PubMed] [Google Scholar]
  93. Ross BD, Bluml S, Cowan R, Danielsen E, Farrow N, Gruetter R. In vivo magnetic resonance spectroscopy of human brain: the biophysical basis of dementia. Biophys Chem 1997; 68: 161–72. [DOI] [PubMed] [Google Scholar]
  94. Scheffel U, Dannals RF, Cline EJ, Ricaurte GA, Carroll FI, Abraham P, Lewin AH, Kuhar MJ. [123/125I]RTI‐55, an in vivo label for the serotonin transporter. Synapse 1992; 11: 134–9. [DOI] [PubMed] [Google Scholar]
  95. Schifano F. Potential human neurotoxicity of MDMA (‘ecstasy’): Subjective self‐reports, evidence from an Italian Drug Addiction Centre and clinical case studies. Neuropsychobiology 2000; 42: 25–33. [DOI] [PubMed] [Google Scholar]
  96. Schmand B, Bakker D, Saan R, Louman J. The Dutch Reading Test for Adults: a measure of premorbid intelligence level. Tijdschr Gerontol Geriatr 1991; 22: 15–19. [PubMed] [Google Scholar]
  97. Semple DM, Ebmeier KP, Glabus MF, O'Carroll RE, Johnstone EC. Reduced in vivo binding to the serotonin transporter in the cerebral cortex of MDMA (‘ecstasy’) users. Br J Psychiatry 1999; 175: 63–9. [DOI] [PubMed] [Google Scholar]
  98. Shepard RN, Metzler J. Mental rotation of three dimensional objects. Science 1971; 171: 701–703. [DOI] [PubMed] [Google Scholar]
  99. Thomasius R, Petersen K, Buchert R, Andresen B, Zapletalova P, Wartberg L, Nebeling B, Schmoldt A. Mood, cognition and serotonin transporter availability in current and former ecstasy (MDMA) users. Psychopharmacology (Berl) 2003; 167: 85–96. [DOI] [PubMed] [Google Scholar]
  100. Turner JJ, Parrott AC. ‘Is MDMA a human neurotoxin?’: diverse views from the discussants. Neuropsychobiology 2000; 42: 42–8. [DOI] [PubMed] [Google Scholar]
  101. Van den Burg W, Saan RJ, Deelman BG. 15‐woordentest. Provisional Manual. Groningen: University Hospital, 1985. [Google Scholar]
  102. Van de Wijngaart G, Braam R, De Bruin D, Fris M, Maalsté N, Verbraeck H. Ecstasy in het uitgaanscircuit (Ecstasy and the Dutch rave scene: A socio‐epidemiologic study on the nature and extent of, and the risks involved in using ecstasy and other party drugs at dance events). Utrecht: Addiction Research Institute, 1997. [Google Scholar]
  103. Verbaten MN. Specific memory deficits in ecstasy users? The results of a meta‐analysis. Hum Psychopharmacol 2003; 18: 281–90. [DOI] [PubMed] [Google Scholar]
  104. Verhulst FC, Berden GFMG, Sanders‐Woudstra JAR. Mental health in Dutch children: (II). The prevalence of psychiatric disorder and relationship between measures. Acta Psychiatr Scand Suppl 1985; 324: 1–45. [DOI] [PubMed] [Google Scholar]
  105. Wareing M, Fisk JE, Murphy PN. Working memory deficits in current and previous users of MDMA (‘ecstasy’). Br J Psychol 2000; 91: 181–8. [DOI] [PubMed] [Google Scholar]
  106. World Health Organization . Composite International Diagnostic Interview. Geneva: WHO, 1992. [Google Scholar]
  107. Zuckerman M, Link K. Construct validity for the sensation‐seeking scale. J Consult Clin Psychol 1968; 32: 420–6. [DOI] [PubMed] [Google Scholar]

Articles from International Journal of Methods in Psychiatric Research are provided here courtesy of Wiley

RESOURCES